Safety And Efficacy Of Oral Administered Cepharanthine In Non-Hospitalized, Asymptomatic Or Mild COVID-19 Patients: A Double-Blind, Randomized, Placebo-Controlled Trial

    January 2025 in “ Scientific Reports ”
    Jianyi Wei, Shupeng Liu, Yuexiang Bian, Lei Li, Biyun Qian, Zixuan Shen, Yan Zhang, Adila Abuduaini, Fuchen Dong, Xin Zhang, Jinhui Li, Yongpei Yu, Weituo Zhang, Jun Wang, Wei Zhai, Qixiang Song, Yu Zheng, Weihua Pan, Lanlan Yu, Qimin Zhan, Ning Zhang, Junhua Zheng, Shuming Pan, Chen Yao, Hai Li
    TLDR Cepharanthine is safe but not effective in significantly reducing COVID-19 recovery time.
    A double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of cepharanthine (CEP) in 262 non-hospitalized, asymptomatic or mild COVID-19 patients. Participants received either 120 mg/day or 60 mg/day of CEP, or a placebo for 5 days. The study found that neither dosage significantly shortened the time to a negative nasopharyngeal swab compared to placebo. However, 60 mg/day CEP showed a slight trend towards reducing the time to negative, particularly in participants with good medication compliance, where it significantly shortened the time by 0.87 days. No serious adverse events were reported, suggesting CEP is safe, but further trials are needed to confirm its efficacy.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results